Retatrutide: the complete research guide.

Retatrutide is a once-weekly injectable that hit a number nobody in obesity research had seen before. In a single 48-week trial, the high dose produced 24.2% mean body-weight reduction. That's the biggest magnitude any drug has ever delivered in a published study.

Obesity affects roughly 42% of US adults. Its downstream costs are large. They include type 2 diabetes, fatty liver disease, sleep apnea and heart disease. Those costs made the GLP-1 class the most-watched drug franchise in medicine. Semaglutide hit roughly 15% in its pivotal trial. Tirzepatide hit 22.5% in SURMOUNT-1. Each generation has pushed the ceiling about 5 percentage points higher.

Retatrutide is the next step on that curve. It is also the first compound with a truly new mechanism. The others were additive.

This guide walks through what retatrutide is. Then why combining three receptors matters. Then what the Phase II trial actually showed. Then what Phase III TRIUMPH still needs to confirm. Then how the side-effect profile stacks up. And last, where the heart-health evidence stands. Our framing throughout is honest. Retatrutide is genuinely transformative biology. But the evidence is Phase II, not Phase III. The difference matters.

What is retatrutide?

Retatrutide is an investigational obesity drug from Eli Lilly. Its development code is LY3437943. It is a 39-amino-acid peptide, built for once-weekly injection. The molecular scaffold is close to tirzepatide. That is Lilly's approved obesity and diabetes drug. The difference is the receptor profile.

Tirzepatide activates two gut hormone receptors: GIP and GLP-1. Both suppress appetite and improve insulin response. Retatrutide adds a third receptor: glucagon.

That glucagon piece is what makes the mechanism new. Glucagon normally reads as the hormone that opposes insulin. It raises blood glucose. So why add it to an obesity-indication drug?

Glucagon receptor activation also drives energy expenditure. It mobilizes stored lipids and promotes hepatic fat oxidation. GLP-1 and GIP together suppress hunger and improve insulin secretion. Co-activate the glucagon arm alongside them. In study subjects it does not appear to raise blood sugar. Instead, preclinical and Phase II data point to an "energy-out" component. That sits on top of the appetite suppression. The other two receptor agonist arms produce that suppression.

The result is the broadest pharmacological lever the obesity field has put in one molecule. GLP-1 brings appetite suppression. GIP brings insulin and adipose effects. Glucagon brings energy burning. The 2023 trial was the first real-world test of whether those three arms actually work together. The answer so far is yes.

One important framing note. Retatrutide is not FDA-approved. It is not EMA-approved. It's in Phase III development under Lilly's TRIUMPH program. Every number we discuss below is Phase II evidence in 338 people over 48 weeks, not Phase III evidence in thousands of people over multiple years. That distinction matters when interpreting the headline numbers.

What did the 2023 Phase II trial actually show?

The Jastreboff trial, published in NEJM in August 2023, enrolled 338 adults with obesity. Participants were randomized to one of five arms: retatrutide 1 mg, 4 mg, 8 mg, 12 mg, or placebo. Treatment ran once weekly for 48 weeks.

The headline numbers come straight from the published paper:

• 12 mg dose: −24.2% mean body weight at 48 weeks
• 8 mg dose: −22.8% mean body weight at 48 weeks
• 4 mg dose: −17.1% mean body weight at 48 weeks
• 1 mg dose: −8.7% mean body weight at 48 weeks
• Placebo: −2.1% mean body weight at 48 weeks

The 24.2% number is the largest documented for any pharmaceutical at the time of publication. It's the headline that reset expectations for what an obesity drug could do.

But the threshold-response number is arguably more useful than the mean. On the 12 mg dose, 83% of participants reached the 15%-or-more body-weight-reduction bar by week 48. On placebo, only 2% hit it. An 83% response rate is the kind of number that predicts downstream wins on diabetes remission and sleep apnea reversal.

The dose-response curve is clean. Each dose increment delivers a meaningful body-weight-reduction increment. The slope only modestly flattens between 8 and 12 mg. That means retatrutide hasn't obviously hit a biological ceiling at the 12 mg dose. Phase III may explore whether higher doses unlock more body-weight reduction, or whether side effects become the limiting factor.

How does it compare to existing GLP-1 drugs?

This is the comparison every metabolic clinician is running. It also requires honesty about the structural unfairness of cross-trial comparisons.

Semaglutide 2.4 mg (Wegovy) hit ~14.9% mean body-weight reduction in STEP-1 at 68 weeks. Tirzepatide 15 mg (Zepbound) hit 22.5% in SURMOUNT-1 at 72 weeks. Retatrutide 12 mg hit 24.2% at just 48 weeks.

At face value, retatrutide is producing about 1.5 to 2 percentage points more body-weight reduction than tirzepatide, in a shorter window.

One other dimension. Tirzepatide's SURMOUNT-1 curve plateaus around week 60 to 72. Retatrutide's 48-week trial ended before its own curve obviously plateaued. The true ceiling on the 12 mg dose may be higher than 24.2% with longer follow-up. The Phase III TRIUMPH trials are running longer follow-up to answer that.

What about side effects?

This is where retatrutide looks like the rest of the class. The most common adverse events were gastrointestinal: nausea, vomiting, diarrhea, constipation. Rates climbed with dose. Events were mostly mild to moderate. Slower titration with lower starting doses mitigated them, but didn't eliminate them.

The compound-specific signal in the Phase II trial was a dose-dependent heart rate increase. It peaked around week 24 and then drifted back toward baseline as treatment continued. The mechanism isn't fully characterized. It's probably tied to glucagon receptor effects on cardiac output. The Phase II trial size of 338 wasn't large enough to detect cardiovascular events at clinically meaningful rates. That question sits squarely with Phase III TRIUMPH and any later cardiovascular outcomes trial.

There's also a theoretical concern about the glucagon arm raising blood glucose, especially in non-diabetic people where the GLP-1 insulin response is weaker. The Phase II data showed no clinically significant hyperglycemia. The GLP-1 and GIP arms appear to dominate. But this is the kind of signal that a larger Phase III population can detect or rule out more confidently.

What about cardiovascular outcomes?

This is the part of the retatrutide story with the biggest open question. Semaglutide has the SELECT trial: roughly 17,600 participants, with a 20% reduction in major cardiovascular events on semaglutide versus placebo in people with established heart disease and obesity. That data shifted semaglutide from a "obesity-indication drug" into a "cardiometabolic risk-reduction drug" in clinical guidelines.

Tirzepatide has SURPASS-CVOT and SURMOUNT-MMO running. Primary readouts are expected over the next few years. Tirzepatide doesn't yet have a SELECT-equivalent positive cardiovascular outcomes signal in published trials.

Retatrutide is further behind. The Phase III TRIUMPH program focuses on body-weight reduction and glycemic outcomes. A SELECT-equivalent cardiovascular outcomes trial for retatrutide would need Phase III completion, regulatory approval, and a separate large outcomes trial. That's a 5 to 7 year timeline from where we sit today. The body-weight-reduction magnitude makes a cardiovascular benefit highly plausible. But plausible isn't the same as demonstrated.

The honest framing for researchers: dedicated cardiovascular outcomes data for retatrutide does not yet exist in the published literature. The body-weight-reduction magnitude observed in Phase II makes cardiometabolic benefit mechanistically plausible, but plausible is not the same as demonstrated in a powered outcomes trial.

Where is Phase III TRIUMPH in the pipeline?

TRIUMPH is Eli Lilly's Phase III development plan for retatrutide. As of 2026, it includes multiple Phase III trials covering obesity (TRIUMPH-1 through TRIUMPH-5), type 2 diabetes, fatty liver disease, and other comorbidities. The primary obesity readouts are expected in the next 12 to 24 months.

The key questions Phase III TRIUMPH needs to answer:

• Does the 24.2% Phase II number hold up at scale? Or does it regress on the way to a 5,000-participant population, the way most compounds do?
• What's the heart-rate effect at scale? The Phase II signal peaked and declined. Larger populations can show whether it predicts real cardiovascular events.
• What's the body-weight-reduction durability past 48 weeks? How does the trajectory compare to where tirzepatide plateaued in SURMOUNT-1?
• How do the GI rates compare to tirzepatide head-to-head? The dual-agonist class runs 60 to 80% GI events. Any clinically meaningful difference matters.
• Does the glucagon arm produce real hepatic effects in MASH? This is where the triple-agonist mechanism becomes uniquely useful, not just additive.

Regulatory status and research context

As of mid-2026, retatrutide has not received regulatory approval in the US, EU, or Canada. The molecule remains investigational. Available as a reference compound for laboratory research, it is supplied for in vitro and preclinical study use only — not for human administration. Formal clinical access is limited to enrollment in the ongoing TRIUMPH Phase III program.

Key pipeline and regulatory considerations for researchers tracking this compound:

• Phase III TRIUMPH enrollment: Multiple TRIUMPH sub-trials are actively recruiting across obesity, type 2 diabetes, and MASH indications. Trial sites and eligibility criteria are listed at ClinicalTrials.gov.
• Projected regulatory timeline: Phase III primary readouts are expected 2026–2027. A potential FDA submission window is 2027–2028, with approval contingent on Phase III outcome data.
• Heart rate signal: The dose-dependent heart rate increase observed in the Jastreboff 2023 Phase II trial (peaking at week 24, then declining) is a pharmacodynamic signal of interest for cardiovascular outcome studies. Phase III populations are sized to characterize it further.
• Compound identity in research: Researchers sourcing retatrutide as a reference compound should confirm chemical identity and purity via COA. Opaque catalog codes (e.g., "FG3-R") do not guarantee structural equivalence to the Phase II trial compound. Identity verification by mass spectrometry is standard practice for reference-grade procurement.